{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:55:33Z","timestamp":1786550133039,"version":"build-2736575974"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1038\/ajg.2017.49","type":"journal-article","created":{"date-parts":[[2017,3,14]],"date-time":"2017-03-14T09:01:43Z","timestamp":1489482103000},"page":"1298-1308","source":"Crossref","is-referenced-by-count":95,"title":["Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia"],"prefix":"10.14309","volume":"112","author":[{"given":"Joel S","family":"Emery","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kuczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danie","family":"La","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Almarzooqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kowgier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemant","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L A","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan J","family":"Feld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210219","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1056\/NEJMra1208642","article-title":"Therapy for hepatitis C virus-related cryoglobulinemic vasculitis.","volume":"369","author":"Campion","year":"2013","journal-title":"N Engl J Med"},{"key":"R2-20-20210219","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.gtc.2015.07.006","article-title":"Extrahepatic manifestations of hepatitis C virus.","volume":"44","author":"Vigano","year":"2015","journal-title":"Gastroenterol Clin N Am"},{"key":"R3-20-20210219","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/ard.2007.081653","article-title":"Rituximab combined with peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis.","volume":"67","author":"Saadoun","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R4-20-20210219","first-page":"51","article-title":"HCV-related cryoglobulinemic glomerulonephritis: Implications of antiviral and immunosuppressive therapies.","volume":"78","author":"Garini","year":"2007","journal-title":"Acta Bio-medica"},{"key":"R5-20-20210219","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12016-007-8070-x","article-title":"Hepatitis C virus infection induced vasculitis.","volume":"35","author":"Cacoub","year":"2008","journal-title":"Clin Rev Allergy Immunol"},{"key":"R6-20-20210219","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1177\/039139880703000306","article-title":"Interferon therapy for HCV-associated glomerulonephritis: meta-analysis of controlled trials.","volume":"30","author":"Fabrizi","year":"2007","journal-title":"Int J Artif Organs"},{"key":"R7-20-20210219","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S0168-8278(02)00067-3","article-title":"Impact of treatment on extra hepatic manifestations in patients with chronic hepatitis C.","volume":"36","author":"Cacoub","year":"2002","journal-title":"J Hepatol"},{"key":"R8-20-20210219","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.dld.2014.05.017","article-title":"Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.","volume":"46","author":"Gragnani","year":"2014","journal-title":"Dig Liver Dis"},{"key":"R9-20-20210219","first-page":"CD010404","article-title":"Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection.","volume":"12","author":"Benstead","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"R10-20-20210219","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1002\/art.10699","article-title":"Interferon- and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.","volume":"46","author":"Cacoub","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R11-20-20210219","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.autrev.2011.01.008","article-title":"Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients.","volume":"10","author":"Pietrogrande","year":"2011","journal-title":"Autoimmun Rev"},{"key":"R12-20-20210219","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/hep.27623","article-title":"Long-term effect of HCV eradication in patients with mixed cryoglobulinemia: a prospective, controlled, open-label, cohort study.","volume":"61","author":"Gragnani","year":"2015","journal-title":"Hepatology"},{"key":"R13-20-20210219","doi-asserted-by":"crossref","first-page":"e000008","DOI":"10.1136\/rmdopen-2014-000008","article-title":"For patients with rheumatic disease and hepatitis C infection: the end of interferon.","volume":"1","author":"Calabrese","year":"2015","journal-title":"RMD Open"},{"key":"R14-20-20210219","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2009-10-245878","article-title":"Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.","volume":"116","author":"Dammacco","year":"2010","journal-title":"Blood"},{"key":"R15-20-20210219","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1182\/blood-2009-11-253948","article-title":"Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.","volume":"116","author":"Petrarca","year":"2010","journal-title":"Blood"},{"key":"R16-20-20210219","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/rheumatology\/kel004","article-title":"Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids.","volume":"45","author":"Quartuccio","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R17-20-20210219","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP2975","article-title":"Hepatitis C cure with antiviral therapy-benefits beyond the liver.","volume":"21","author":"Soriano","year":"2015","journal-title":"Antivir Ther (Lond)"},{"key":"R18-20-20210219","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/hep.28297","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents.","volume":"63","author":"Sise","year":"2016","journal-title":"Hepatology"},{"key":"R19-20-20210219","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia.","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"key":"R20-20-20210219","doi-asserted-by":"crossref","first-page":"31","DOI":"10.7326\/0003-4819-124-1_Part_1-199601010-00006","article-title":"Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia.","volume":"124","author":"Zignego","year":"1996","journal-title":"Ann Intern Med"},{"key":"R21-20-20210219","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"R22-20-20210219","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1002\/art.22168","article-title":"Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis: A long-term followup study.","volume":"54","author":"Saadoun","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R23-20-20210219","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1136\/annrheumdis-2015-208339","article-title":"Sofosbuvir plus ribavirin for hepatitis C virus-associated cryoglobulinaemia vasculitis: VASCUVALDIC study.","volume":"75","author":"Saadoun","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R24-20-20210219","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1002\/art.24703","article-title":"Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup study of thirty-two patients.","volume":"60","author":"Terrier","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R25-20-20210219","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/MD.0b013e3182a5cf71","article-title":"Life-threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients.","volume":"92","author":"Retamozo","year":"2013","journal-title":"Medicine"},{"key":"R26-20-20210219","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1001\/archinte.165.1.101","article-title":"Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias.","volume":"165","author":"Monti","year":"2005","journal-title":"Arch Intern Med"},{"key":"R27-20-20210219","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/ki.1995.78","article-title":"Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis.","volume":"47","author":"Tarantino","year":"1995","journal-title":"Kidney Int"},{"key":"R28-20-20210219","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2007.06.064","article-title":"Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients.","volume":"133","author":"Vigano","year":"2007","journal-title":"Gastroenterology"},{"key":"R29-20-20210219","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2014.08.015","article-title":"PegIFNribavirinprotease inhibitor combination in severe hepatitis C virus-associated mixed cryoglobulinemia vasculitis.","volume":"62","author":"Saadoun","year":"2015","journal-title":"J Hepatol"},{"key":"R30-20-20210219","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/BOR.0b013e32835b15f7","article-title":"Cryoglobulinemia vasculitis: an update.","volume":"25","author":"Terrier","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"R31-20-20210219","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/apt.13633","article-title":"Systematic review: Current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.","volume":"43","author":"Majumdar","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R32-20-20210219","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hep.20087","article-title":"Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes.","volume":"39","author":"Ducoulombier","year":"2004","journal-title":"Hepatology"},{"key":"R33-20-20210219","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jhep.2004.01.019","article-title":"HVR-1 quasispecies modifications occur early and are correlated to initial but not sustained response in HCV-infected patients treated with pegylated-or standard-interferon and ribavirin.","volume":"40","author":"Abbate","year":"2004","journal-title":"J Hepatol"},{"key":"R34-20-20210219","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jhep.2004.10.031","article-title":"Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study.","volume":"42","author":"Mazzaro","year":"2005","journal-title":"J Hepatol"},{"key":"R35-20-20210219","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/00325481.2015.1021660","article-title":"Persistence of mixed cryoglobulinemia despite cure of hepatitis C with new oral antiviral therapy including direct-acting antiviral sofosbuvir: a case series.","volume":"127","author":"Cornella","year":"2015","journal-title":"Postgraduate Med"},{"key":"R36-20-20210219","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/annrheumdis-2013-203883","article-title":"Hepatitis C virus-induced vasculitis: therapeutic options.","volume":"73","author":"Cacoub","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R37-20-20210219","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/0002-9343(87)90904-1","article-title":"Treatment of idiopathic mixed cryoglobulinemia with alpha interferon.","volume":"83","author":"Bonomo","year":"1987","journal-title":"Am J Med"},{"key":"R38-20-20210219","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1056\/NEJM199403173301104","article-title":"Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus.","volume":"330","author":"Misiani","year":"1994","journal-title":"N Engl J Med"},{"key":"R39-20-20210219","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1473-3099(05)70053-0","article-title":"Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations.","volume":"5","author":"Sansonno","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"R40-20-20210219","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/art.23305","article-title":"Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.","volume":"58","author":"Landau","year":"2008","journal-title":"Arthritis Rheum"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000434-201708000-00020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:15:41Z","timestamp":1786547741000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201708000-00020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2017.49","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]}}}